Celcuity Inc.
CELCNasdaq
$88.38
↑ +0.1%Jul 17 close · end-of-day
Price
1Y↑ +537.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.8B
Enterprise Value
$4.6B
P/E
—
P/S
—
P/B
89.9
EV/EBITDA
—
PEG
—
FCF Yield
-3.6%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$192.9M
Free Cash Flow (TTM)
-$172.9M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-360.4%
ROIC
—
Debt / Equity
2.6
Net Cash
$249.2M
Return 1Y
+542.8%
Company profile
Celcuity Inc. focuses on the development of molecularly targeted therapies for cancer patients in the United States. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3k signaling activity in breast and ovarian tumor cells.
- CEO
- Brian F. Sullivan
- Sector
- Services
- Industry
- Healthcare
- Employees
- 40
- Headquarters
- Minnesota
- Website
- celcuity.com
Management & directors
- Laing Lance G.Chief Science Officer
- Sullivan Brian FChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
CELC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.97↑ +12.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.6M | -$28.4M | -$39.4M | -$66.2M | -$113.3M | -$172.2M |
| Net income | -$9.5M | -$29.6M | -$40.4M | -$63.8M | -$111.8M | -$177.0M |
| Diluted EPS | — | — | -$2.64 | -$2.69 | -$2.83 | -$3.79 |
| Operating cash flow | -$7.1M | -$20.3M | -$36.0M | -$53.8M | -$83.5M | -$153.3M |
| Free cash flow | -$7.2M | -$20.4M | -$36.2M | -$53.9M | -$83.7M | -$153.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$24.3M | -$30.1M | -$36.4M | -$36.1M | -$44.0M | -$42.8M | -$49.2M | -$50.5M |
| Net income | -$23.7M | -$29.8M | -$36.7M | -$37.0M | -$45.3M | -$43.8M | -$51.0M | -$52.8M |
| Diluted EPS | -$0.62 | -$0.70 | -$0.87 | -$0.86 | -$1.04 | -$0.92 | -$0.97 | -$0.97 |
| Operating cash flow | -$18.1M | -$20.6M | -$27.8M | -$35.9M | -$36.2M | -$44.8M | -$36.4M | -$55.1M |
| Free cash flow | -$18.1M | -$20.6M | -$27.8M | -$35.9M | -$36.3M | -$44.9M | -$36.5M | -$55.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 15, 2026
Jul 14, 2026
Jun 19, 2026
Jun 4, 2026
- 46d agoCelcuity (CELC) Weighs Dilution Against Drug Development After $500 Million Convertible Note Offeringfinance.yahoo.com
- 46d agoCelcuity (CELC) Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patientsfinance.yahoo.com
- 46d agoCelcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-14 | BAKER BROS. ADVISORS LP | Sale | 2,838,632 | $102.50 | $291.0M | filing |
| 2026-07-14 | BAKER BROS. ADVISORS LP | Sale | 261,368 | $102.50 | $26.8M | filing |
| 2026-06-05 | Dalvey David | Award | 1,530 | $0.00 | $0.00 | filing |
| 2026-06-05 | ROMP CHARLES R | Award | 1,530 | $0.00 | $0.00 | filing |
| 2026-06-05 | NIGON RICHARD | Award | 1,530 | $0.00 | $0.00 | filing |
| 2026-06-05 | Buller Richard E | Award | 1,530 | $0.00 | $0.00 | filing |
| 2026-06-05 | Furcht Leo | Award | 1,530 | $0.00 | $0.00 | filing |
| 2026-06-05 | Murphy Polly A. | Award | 1,530 | $0.00 | $0.00 | filing |
| 2026-06-02 | Laing Lance G.· Chief Science Officer | Option exercise | 1,000 | $9.89 | $9,890.00 | filing |
| 2026-05-19 | Buller Richard E | Gift | 1,029 | $0.00 | $0.00 | filing |
| 2026-05-19 | Buller Richard E | Gift | 1,029 | $0.00 | $0.00 | filing |
| 2026-05-04 | Dalvey David | Sale | 25,000 | $140.68 | $3.5M | filing |
| 2026-05-04 | Buller Richard E | Sale | 2,825 | $142.04 | $401,251.14 | filing |
| 2026-05-04 | Buller Richard E | Sale | 2,301 | $141.03 | $324,503.36 | filing |
| 2026-05-04 | Buller Richard E | Sale | 1,670 | $139.58 | $233,103.94 | filing |
| 2026-05-04 | Buller Richard E | Sale | 1,289 | $137.00 | $176,593.00 | filing |
| 2026-05-04 | Buller Richard E | Sale | 550 | $139.00 | $76,447.53 | filing |
| 2026-05-04 | Buller Richard E | Sale | 365 | $143.24 | $52,281.80 | filing |
| 2026-05-04 | Buller Richard E | Option exercise | 9,000 | $5.10 | $45,900.00 | filing |
| 2026-04-09 | NIGON RICHARD | Gift | 10,000 | $0.00 | $0.00 | filing |
| 2026-03-31 | Buller Richard E | Sale | 2,325 | $110.11 | $255,995.75 | filing |
| 2026-03-31 | Buller Richard E | Sale | 675 | $110.83 | $74,808.09 | filing |
| 2026-03-31 | Buller Richard E | Option exercise | 3,000 | $5.10 | $15,300.00 | filing |
| 2026-02-11 | ROMP CHARLES R | Award | 215 | $0.00 | $0.00 | filing |
| 2026-01-27 | Dalvey David | Sale | 20,000 | $120.03 | $2.4M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.